Tenax Therapeutics  Inc (Nasdaq: TENX)  a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs  today announced the registration of their Phase 2 clinical trial in the use of levosimendan for treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF) on ClinicalTrials